Presentation is loading. Please wait.

Presentation is loading. Please wait.

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial  Sonja Ständer, MD, Paul Kwon, MD,

Published byEduarda Belmonte Modified over 5 years ago

Similar presentations

Presentation on theme: "Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial  Sonja Ständer, MD, Paul Kwon, MD,"— Presentation transcript:

1 Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial  Sonja Ständer, MD, Paul Kwon, MD, Joe Hirman, PhD, Andrew J. Perlman, MD, PhD, Elke Weisshaar, MD, Martin Metz, MD, Thomas A. Luger, MD  Journal of the American Academy of Dermatology  Volume 80, Issue 5, Pages (May 2019) DOI: /j.jaad Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Changes from baseline over time. A, Percentage change from baseline in mean average itch visual analog scale (VAS) score at weeks 2, 4, and 8. Asterisks indicate P < .05 for the mean difference of serlopitant versus placebo. B, Forest plot of average intensity with standard error (SE) for average itch VAS score change from baseline at weeks 4 and 8, by subgroup (intention-to-treat population). Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Changes from baseline over time. Percentage change from baseline in least squares mean average itch numeric rating scale (NRS) score at weeks 2, 4, and 8. Asterisk indicates P ≤ .05 for the mean difference of serlopitant versus placebo. SE, Standard error. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial  Sonja Ständer, MD, Paul Kwon, MD,"

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shuangbai San for Treating Primary Liver Cancer Patients With Cancer Pain  Xiaowei.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shuangbai San for Treating Primary Liver Cancer Patients With Cancer Pain  Xiaowei.
Tsung-Yu Tsai, MD, Yu-Chen Huang, MD 

Tsung-Yu Tsai, MD, Yu-Chen Huang, MD 
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle  Kathryn.

A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle  Kathryn.
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Daniel S. Winchester, MD, Thomas L. Hocker, MD, Randall K. Roenigk, MD 

Daniel S. Winchester, MD, Thomas L. Hocker, MD, Randall K. Roenigk, MD 
Psoriasis and suicidality: A systematic review and meta-analysis

Psoriasis and suicidality: A systematic review and meta-analysis
Effectiveness of low-level laser therapy in lichen planopilaris

Effectiveness of low-level laser therapy in lichen planopilaris
Baldness reversed by chemotherapy

Baldness reversed by chemotherapy
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.
Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,
Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective β-adrenergic blocker  Chia-Chi Hsu, MD,

Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective β-adrenergic blocker  Chia-Chi Hsu, MD,
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.
Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial  William Tuong,

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial  William Tuong,

Similar presentations

Ads by Google